Milestone Pharmaceuticals Inc - Asset Resilience Ratio
Milestone Pharmaceuticals Inc (MIST) has an Asset Resilience Ratio of 40.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MIST working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Milestone Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Milestone Pharmaceuticals Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Milestone Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Milestone Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $35.90 Million | 40.91% |
| Total Liquid Assets | $35.90 Million | 40.91% |
Asset Resilience Insights
- Very High Liquidity: Milestone Pharmaceuticals Inc maintains exceptional liquid asset reserves at 40.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Milestone Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Milestone Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Milestone Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.78% | $44.38 Million | $75.50 Million | -10.66pp |
| 2023-12-31 | 69.45% | $52.24 Million | $75.23 Million | -7.01pp |
| 2022-12-31 | 76.46% | $56.95 Million | $74.48 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $119.85 Million | -- |
| 2020-12-31 | 46.67% | $70.00 Million | $149.97 Million | +46.64pp |
| 2018-12-31 | 0.03% | $29.00K | $88.08 Million | -58.08pp |
| 2017-12-31 | 58.11% | $16.03 Million | $27.59 Million | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more